FindTrial
Sign In

RADIOTHERAPY STUDY WITH MODULATION OF INTENSITY, WITH TARGET IDENTIFICATION ON METABOLIC BASIS PET DRIVEN, IN ADVANCED CERVICO-FACIAL TUMORS, USING TOMOTERAPY EQUIPMENT FOR CONCOMITANT BOOST EXECUTION. PHASE I AND II DOSE ESCALATION.

RADIOTHERAPY STUDY WITH MODULATION OF INTENSITY, WITH TARGET IDENTIFICATION ON METABOLIC BASIS PET DRIVEN, IN ADVANCED CERVICO-FACIAL TUMORS, USING TOMOTERAPY EQUIPMENT FOR CONCOMITANT BOOST EXECUTION. PHASE I AND II DOSE ESCALATION.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004732-32-IT
Enrollment
45
Registered
2005-10-25
Start date
2004-12-02
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SQUAMOCELLULAR CARCINOMA TREATMENT MedDRA version: 6.1 Level: PT Classification code 10031103

Interventions

Trade Name: CISPLATINO SEGIX*IV 1FL100ML Pharmaceutical Form: Solution for infusion INN or Proposed INN: Cisplatin CAS Number: 15663-27-1 Concentration unit: mg milligram(s) Concentration type: equal

Sponsors

OSPEDALE S. RAFFAELE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026